Page 6,710«..1020..6,7096,7106,7116,712..6,7206,730..»

Vaccine For Blocking Nicotine Chemicals Before They Reach The Brain Shows Promise

Posted: Published on July 3rd, 2012

Editor's Choice Main Category: Smoking / Quit Smoking Also Included In: Immune System / Vaccines Article Date: 02 Jul 2012 - 11:00 PDT Current ratings for: Vaccine For Blocking Nicotine Chemicals Before They Reach The Brain Shows Promise 5 (1 votes) 5 (1 votes) The study, published in the journal Science Translational Medicine describes that a single dose of the novel vaccine protects mice against a life-long addiction against nicotine. The vaccine uses the animal's liver as a production site to continuously produce antibodies that instantly gobble up nicotine the moment it enters the bloodstream, and therefore prevents the chemical from reaching the brain and heart. Leading researcher, Dr. Ronald G. Crystal, chairman and professor of Genetic Medicine at Weill Cornell Medical College explains: He continues saying: "Our vaccine allows the body to make its own monoclonal antibodies against nicotine, and in that way, develop a workable immunity." Dr. Crystal stated that the reason why earlier nicotine vaccines failed in clinical trials was because they all directly deliver nicotine antibodies. Their effect only lasted a few weeks and therefore required repeated, costly injections. He adds that this impractical, passive vaccine also delivered inconsistent results, which could potentially be because each … Continue reading →

Comments Off on Vaccine For Blocking Nicotine Chemicals Before They Reach The Brain Shows Promise

Moffitt Cancer Center Study Validates Activity of Rare Genetic Variant in Glioma

Posted: Published on July 3rd, 2012

Newswise Researchers at Moffitt Cancer Center working with colleagues at three other institutions have validated a link between a rare genetic variant and the risk of glioma, the most common and lethal type of brain tumor. The validation study also uncovered an association between the same rare genetic variant and improved rates of survival for patients with glioma. The study, the first to confirm a rare susceptibility variant in glioma, appeared in a recent issue of the Journal of Medical Genetics, a journal published by the British Medical Association. "Glioma is a poorly understood cancer with high morbidity and devastating outcomes," said study lead author Kathleen M. Egan, Sc.D., interim program leader of Cancer Epidemiology and vice chair of the Department of Cancer Epidemiology. "However, the discovery of the association of the TP53 genetic variant rs78378222 with glioma provides new insights into these tumors and offers better prospects for identifying people at risk." According to the authors, their study "genotyped' the single nucleotide polymorphism (SNP, or "snip") rs78378222 in TP53, an important tumor suppressor gene. The researchers said the SNP disrupts the TP53 signal and, because of its activity, has been linked to a variety of cancers. This study linked … Continue reading →

Comments Off on Moffitt Cancer Center Study Validates Activity of Rare Genetic Variant in Glioma

Activity of rare genetic variant in glioma validated

Posted: Published on July 3rd, 2012

ScienceDaily (July 2, 2012) Researchers at Moffitt Cancer Center working with colleagues at three other institutions have validated a link between a rare genetic variant and the risk of glioma, the most common and lethal type of brain tumor. The validation study also uncovered an association between the same rare genetic variant and improved rates of survival for patients with glioma. The study, the first to confirm a rare susceptibility variant in glioma, appeared in a recent issue of the Journal of Medical Genetics, a journal published by the British Medical Association. "Glioma is a poorly understood cancer with high morbidity and devastating outcomes," said study lead author Kathleen M. Egan, Sc.D., interim program leader of Cancer Epidemiology and vice chair of the Department of Cancer Epidemiology. "However, the discovery of the association of the TP53 genetic variant rs78378222 with glioma provides new insights into these tumors and offers better prospects for identifying people at risk." According to the authors, their study "genotyped' the single nucleotide polymorphism (SNP, or "snip") rs78378222 in TP53, an important tumor suppressor gene. The researchers said the SNP disrupts the TP53 signal and, because of its activity, has been linked to a variety of cancers. … Continue reading →

Comments Off on Activity of rare genetic variant in glioma validated

ACT Announces Second Patient with Stargardt’s Disease Treated in EU Clinical Trial

Posted: Published on July 2nd, 2012

MARLBOROUGH, Mass.--(BUSINESS WIRE)-- Advanced Cell Technology, Inc. (ACT; OTCBB: ACTC), a leader in the field of regenerative medicine, today announced treatment of the second patient in its Phase 1/2 clinical trial for Stargardts macular dystrophy (SMD) using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs). The surgery was performed on Friday, June 29 at Moorfields Eye Hospital in London, the same site as the first patient treatment in January, by a team of surgeons led by Professor James Bainbridge, consultant surgeon at Moorfields and Chair of Retinal Studies at University College London. The procedure was successfully performed without any complications. ACT and Moorfields Eye Hospital recently received clearance from the Data and Safety Monitoring Board (DSMB) to treat the final two patients in the first cohort of this clinical trial. We are very pleased to continue our forward momentum with both our U.S. trials and our European trial, commented Gary Rabin, chairman and CEO. It was less than a month ago that we received DSMB approval to treat the second and third patients in our E.U. trial, and it is very gratifying to have already completed dosing of the second. It is a pleasure to be … Continue reading →

Posted in Mesenchymal Stem Cells | Comments Off on ACT Announces Second Patient with Stargardt’s Disease Treated in EU Clinical Trial

SONA: Stem cell therapy, kaya raw makapagpabata ng pangangatawan – Video

Posted: Published on July 2nd, 2012

02-07-2012 09:43 State of the Nation is a nightly newscast anchored by award-winning broadcast journalist, Jessica Soho. It airs Mondays to Fridays at 9:00 PM (PHL Time) on GMA News TV Channel 11. For more videos from State of the Nation, visit fthenation. Follow this link: SONA: Stem cell therapy, kaya raw makapagpabata ng pangangatawan - Video … Continue reading →

Posted in Mesenchymal Stem Cells | Comments Off on SONA: Stem cell therapy, kaya raw makapagpabata ng pangangatawan – Video

Prochymal Significantly Reduces Hypertrophy, Arrhythmia and Progression to Heart Failure in Patients Suffering a Heart …

Posted: Published on July 2nd, 2012

COLUMBIA, Md.--(BUSINESS WIRE)-- Osiris Therapeutics, Inc. (OSIR), announced today interim one-year results from its groundbreaking clinical trial evaluating Prochymal (remestemcel-L) for the treatment of patients experiencing first-time acute myocardial infarction. The trial is the largest study of allogeneic or "off-the-shelf" stem cells ever conducted in heart attack patients. A total of 220 patients were given a single infusion of either Prochymal or placebo through a standard intravenous line within seven days of an acute heart attack. Cardiac MRI assessments were conducted for six months following infarct to evaluate cardiac remodeling. Patients receiving Prochymal had significantly less cardiac hypertrophy, as measured by cardiac MRI, compared to patients receiving placebo (p … Continue reading →

Posted in Mesenchymal Stem Cells | Comments Off on Prochymal Significantly Reduces Hypertrophy, Arrhythmia and Progression to Heart Failure in Patients Suffering a Heart …

Low-Intensity Shockwave Therapy by Medispec Ensures Long-Lasting Treatment for Erectile Dysfunction

Posted: Published on July 2nd, 2012

GERMANTOWN, Maryland, July 2, 2012 /PRNewswire/ -- Medispec [http://www.medispec.com ], a world leader in non-invasive medical solutions, announced today that its ED-1000 [http://www.medispec.com/solutions/erectile-disfunction ] solution has been found to be an effective treatment for erectile dysfunction (ED) by leading urologists around the world. The solution has been proven as a clinically effective alternative to pharmacological solutions (Phosphodiesterase 5 inhibitors) - such as Cialis, Viagra or Levitra - and dramatically reduces the need for treatments that require vacuum pumps, injections or implants. As a non-invasive, drug-free treatment, the ED-1000 [http://www.medispec.com/solutions/erectile-disfunction ] triggers the bodys natural repair mechanisms, returning spontaneity to the bedroom. The technology - designed specifically to treat the underlying cause of vascular-related ED - is based on the use of low-intensity extracorporeal shockwaves to improve the volume of blood flow within the body. The shockwaves stimulate the creation of new microvascular blood vessel networks that increase the blood supply to erectile tissue. Extensive clinical trials have shown that the increased blood supply enables the patient to achieve and maintain firm erections for a minimum of two years following treatment. The twenty minute ED-1000 [http://www.medispec.com/solutions/erectile-disfunction ] treatment - repeated several times over a number of weeks - has produced positive … Continue reading →

Posted in Erectile Dysfunction | Comments Off on Low-Intensity Shockwave Therapy by Medispec Ensures Long-Lasting Treatment for Erectile Dysfunction

Equity Briefing : Ampio Pharmaceuticals, Amylin Pharmaceuticals and Cytori Therapeutics moving higher

Posted: Published on July 2nd, 2012

Ampio Pharmaceuticals, Inc. (AMPE) is showing solid up movement with a gain of 11.22% to $5.65. The company announced an agreement with India-based Syngene to create a combination product to treat both premature ejaculation and erectile dysfunction in a Phase III trial. The resulted product would be known as Zertane-ED, will be used in trials in South Korea with the biopharmaceutical company`s partner Daewoong Co., which will finance and conduct the trials. Amylin Pharmaceuticals, Inc. (AMLN) added 8.83% to $30.69 and made a new 52-week high of $30.75. This morning Bristol Myers Squibb Co.(BMY) agreed to buy the company for $5.3 billion or $31 per share in cash. Following an acquisition of Amylin, analyst at Piper Jaffray issued a positive note on various biotech stocks and stated those companies would be an acquisition target. BioMarin Pharmaceutical Inc.(BMRN) climbed 1.47 (3.71%) to $41.05, Theravance Inc(THRX) added 1.77 (7.94%) at $23.99, Affymax, Inc.(AFFY) rose 0.19 (1.48%) to $13.07 and Rigel Pharmaceuticals, Inc.(RIGL) surged 0.13 (1.40%) to $9.43. Cytori Therapeutics Inc. (CYTX) extended its uptrend and rose another 9.26% to $2.95. The stock has been showing solid buying since early July and went up all the way from $2.05 to $2.95 in about … Continue reading →

Posted in Premature Ejaculation | Comments Off on Equity Briefing : Ampio Pharmaceuticals, Amylin Pharmaceuticals and Cytori Therapeutics moving higher

Ampio Contracts with Syngene to Manufacture Zertane-ED(TM), its Recently Patented Combination Drug to Treat both …

Posted: Published on July 2nd, 2012

Greenwood Village, CO//PRNewswire via COMTEX/ -- Ampio Pharmaceuticals, Inc. /quotes/zigman/5133505/quotes/nls/ampe AMPE +9.84% , a biopharmaceutical company conducting clinical trials on its three lead drugs (Ampion(TM), Optina(TM) & Zertane(TM)), licensing distribution of these drugs and developing additional new drugs, today announced that it is proceeding with the development plan for a combination product to treat both premature ejaculation (PE) and erectile dysfunction (ED). The positive pre-IND meeting in June with the FDA gave the company clear guidance for the two concurrent pivotal trials necessary for approval of Zertane(TM) to treat PE in the USA. Vaughan Clift, MD, Ampio's Chief Regulatory Officer, noted "Contrary to rumors that the FDA did not recognize PE as a treatable ailment, the FDA has expressly adopted the definition of PE as a disease condition, using the definition of Premature Ejaculation provided by the International Society for Sexual Medicine (ISSM) Ad Hoc Committee (i.e., premature ejaculation is characterized by ejaculation which always or nearly always occurs prior to or within about one minute of vaginal penetration; and inability to delay ejaculation on all or nearly all vaginal penetrations; and negative personal consequences, such as distress, bother, frustration and/or the avoidance of sexual intimacy.*) This definition fully complements … Continue reading →

Posted in Premature Ejaculation | Comments Off on Ampio Contracts with Syngene to Manufacture Zertane-ED(TM), its Recently Patented Combination Drug to Treat both …

Ampio Contracts with Syngene to Manufacture Zertane-ED™, its Recently Patented Combination Drug to Treat both …

Posted: Published on July 2nd, 2012

GREENWOOD VILLAGE, Colo., July 2, 2012 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (AMPE), a biopharmaceutical company conducting clinical trials on its three lead drugs (Ampion, Optina & Zertane), licensing distribution of these drugs and developing additional new drugs, today announced that it is proceeding with the development plan for a combination product to treat both premature ejaculation (PE) and erectile dysfunction (ED). The positive pre-IND meeting in June with the FDA gave the company clear guidance for the two concurrent pivotal trials necessary for approval of Zertane to treat PE in the USA. (Logo: http://photos.prnewswire.com/prnh/20120516/MM09116LOGO) Vaughan Clift, MD, Ampio's Chief Regulatory Officer, noted "Contrary to rumors that the FDA did not recognize PE as a treatable ailment, the FDA has expressly adopted the definition of PE as a disease condition, using the definition of Premature Ejaculation provided by the International Society for Sexual Medicine (ISSM) Ad Hoc Committee (i.e., premature ejaculation is characterized by ejaculation which always or nearly always occurs prior to or within about one minute of vaginal penetration; and inability to delay ejaculation on all or nearly all vaginal penetrations; and negative personal consequences, such as distress, bother, frustration and/or the avoidance of sexual intimacy.*) This definition fully … Continue reading →

Posted in Premature Ejaculation | Comments Off on Ampio Contracts with Syngene to Manufacture Zertane-ED™, its Recently Patented Combination Drug to Treat both …

Page 6,710«..1020..6,7096,7106,7116,712..6,7206,730..»